Spero Therapeutics Announces Publication In PLoS Pathogens Describing Potential Strategy For Combating Resistant Gram-Negative Bacteria
8/22/2014 10:52:38 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies for treatment of bacterial infections, announced the publication of a paper available online today and in the August issue of the journal PLoS Pathogens that describes the identification and optimization of novel, small molecule compounds designed to silence the bacterial MVfR (PqsR) pathway, known to control virulence of the opportunistic bacterial pathogen Pseudomonas aeruginosa. These new compounds effectively blocked the pathogen both in vitro and in vivo and are the first known to restrict the ability of bacteria to form antibiotic-tolerant cells. Consequently they proved to be very effective at preventing persistent infection in infectious disease models.
Help employers find you! Check out all the jobs and post your resume.
comments powered by